Biography
Emma D’Arpino is an associate in Weil’s Antitrust group. Her practice focuses on transactional regulatory clearance for mergers and acquisitions, government investigations, and antitrust counseling. She has experience across a wide range of industries including oil and gas, private equity, technology, and pharmaceuticals.
Emma also maintains an active pro bono practice, which as of late has included work partnering with the Washington Lawyers’ Committee for Civil Rights and Urban Affairs (WLC).
Emma received her J.D. from Georgetown University Law Center and earned her B.A., with distinction, in English and History from the University of Virginia.
Emma’s recent experience includes serving on Weil teams representing:
- ChampionX Corporation in its pending $7.8B sale to SLB.
- Sanofi on its $2.2 billion acquisition of Inhibrx, Inc., a publicly traded clinical-stage biopharmaceutical company.
- Lone Star Funds, a global private equity fund, in its multi-billion dollar sale of construction chemicals company, MBCC Group, to Swiss multinational specialty company Sika AG.
- Individuals in U.S. Department of Justice grand jury cartel investigations.